Azilect Slows Progression Of Parkinson's Disease

Parkinson's disease progression slows down in phase III clinical study of ADAGIO that used Azilect 1mg tablets. Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect. Lundbeck markets Azilect® in Europe. In the three major European markets, the United Kingdom, Germany and France, Teva and Lundbeck co-promote Azilect®. ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group... [read full story]